News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.
Adolescent self-harm often goes unreported. Serious self-harm (which includes suicide attempts and self-cutting) is one of the top five causes of acute medical admission to hospital, and it is young people aged 16-24 who have the highest admission rates.
A new preclinical model of pulmonary arterial hypertension may lead to improved research and ultimately better therapies for this life-threatening problem, according to its developers, researchers at the University of South Alabama.
A selection of health policy stories from Minnesota, Colorado, New York, Delaware, Georgia, Oregon, Connecticut, Pennsylvania, Arizona, Massachusetts and California.
› Verified 4 days ago